Drugs / Ginkgolides Meglumine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02233972 | Aug → Oct 2014 | — | Jiangsu Kanion Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02264535 | Jun → Nov 2014 | allergic disease | Jiangsu Kanion Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginkgolides Meglumine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02233972 ↗ |
| Route | Intravenous | “intravenous drip” NCT02233972 ↗ |